学术学位硕导
--> 职称：副教授
学院：附属肿瘤医院
cxxxxcyd@gmail.com
专业：妇产科学
个人简介
专业技术职称及职位：主任医师，1996年始在江苏省肿瘤医院妇瘤外科工作，现为中国抗癌协会妇科肿瘤专业委员会全国青年委员。陈小祥，博士，主任医师，从事妇科肿瘤工作20年，现任中国抗癌协会妇科肿瘤专业委员会全国青年委员。Gynecologic Oncology Research and Practice杂志学术编辑。 Plos one, Gyneclogy oncology, International Journal of Gynecologic Cancer，Chemotherapy等杂志审稿人。专业领域：妇科肿瘤临床及基础研究，主要兴趣：妇科恶性肿瘤的临床诊治特别是靶向治疗药物研究；妇科恶性肿瘤发病分子机制研究；卵巢恶性肿瘤耐药机制及纳米药物研发；卵巢恶性肿瘤干细胞研究（EMT等）；卵巢癌生物标记物研究。接受教育、进修履历时间大学或机构专业职位01/2014-03/2014上海交通大学附属仁济医院妇科肿瘤微创治疗进修09/2011–10/2012MD Anderson Cancer Center (德克萨斯大学)妇科肿瘤临床与实验研究访问副教授07/2011–07-2013东南大学生物科学与医学工程学院肿瘤纳米科学与技术博士后09/2008–06/2011南京大学医学院肿瘤学博士12/2010–01/2011阳明大学医学院荣民总医院（台湾）妇科肿瘤访问学者09/2003–06/2006徐州医学院肿瘤学硕士09/1991–06/1996上海医科大学临床医学院临床医学学士 论文、论著（通讯作者*）：1.Xu X, Wang Y, Guo W, Zhou Y, Lv C, Chen X*, Liu K*. The significance of the alteration of 8-OHdG in serous ovarian carcinoma. J Ovarian Res. 2013;6: 74. (2012 if : 2.429)2.Xia Xu, Xiaoxiang Chen*, Zhiqin Dai, Fei Deng, Junwei Qu, Jing Ni. Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer. Journal of Experimental & Clinical Cancer Research 2013, 32:61. (2012 if : 3.066)3.Xiaoxiang Chen, Jing Zhang, Zhihong, Zhang, Hongxia Li, Wenjun Cheng, Jinsong Liu. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathology 2013 Nov;44(11):2373-84. (2012 if : 2.843)4.Xia Xu, Hua Dai, Yibing Zhao, Yan Wang, Xinyu Xu, Zhiying Qian, Jinhua Wang, Xiaoxiang Chen*. In Vitro Chemosensitivity Assay of Ascites in Epithelial Ovarian Cancer. European Journal of Gynaecological Oncology 2013, Dec 34: 559-564. (2012 if : 0.577)5.Xia Xu, Yan Wang, Fang Wang, Lizhou Jia, Yiqin Zhou, Fei Deng, Junwei Qu, Bifang Zhou, Aifeng Meng, Bole Fu, Xiaoxiang Chen*, Zhiying Qian* and Jinhua Wang*. Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer. Journal of Ovarian Research 2013, 13;6(1):31. (2012 if : 2.429)6.Wang F, Ye Y, Xu X, Zhou X, Wang J, Chen X*. CA-125--indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J Ovarian Res. 2013, 13;6(1):14. (2012 if : 2.429)7.Xie H, Xia K, Rong H, Chen X*. Genetic polymorphism in hOGG1 is associated with triple-negative breast cancer risk in Chinese Han women. Breast. 2013 Jan 29: 707-712. (2012 if : 1.967)8.Xiaoxiang Chen, Jing Zhang, Doo Young Chang, Jianfei Huang, Xuan Wang, Lizhou Jia, Daniel G. Rosen, Wei Zhang, Da Yang, David M. Gershenson, MD, Anil K. Sood, Robert C. Bast, Jr., MD, *, Jinsong Liu. CA-125 Le
发表论文:
Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma
In Vitro Chemosensitivity Assay of Ascites in Epithelial Ovarian Cancer
CA-125--indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery
Genetic polymorphism in hOGG1 is associated with triple-negative breast cancer risk in Chinese Han women
CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer
Functional Polymorphisms of the hOGG1 Gene Confer Risk to Type 2 Epithelial Ovarian Cancer in Chinese
Two functional variations in 5'-UTR of hoGG1 gene associated with the risk of breast cancer in Chinese
Xu X, Wang Y, Guo W, Zhou Y, Lv C, Chen X*, Liu K*. The significance of the alteration of 8-OHdG in serous ovarian carcinoma
Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
鞘内注射甲氨蝶呤治疗绒毛膜细胞癌脑转移9 例疗效分析
教材专著:
妇科肿瘤诊疗新进展
科研成果:
目前承担的科研项目:
8-OH-dG切除修复缺陷影响PARP-1抑制对浆液性卵巢癌治疗作用的机制研究
CDX2在卵巢粘液性癌中作用的研究
hOGG1基因遗传变异与II型卵巢癌易感机制研究
8-OHdG糖苷酶1基因变异与卵巢癌风险研究
8-OH-dG切除修复缺陷影响PARP-1抑制对浆液性卵巢癌治疗作用的机制研究
hOGG1基因5'-UTR变异与卵巢癌风险及分子基础研究
已经完成的科研项目:
8-OH-dG切除修复缺陷影响PARP-1抑制对浆液性卵巢癌治疗作用的机制研究
hOGG1基因遗传变异与II型卵巢癌易感机制研究
8-OHdG糖苷酶1基因变异与卵巢癌风险研究
hOGG1基因5'-UTR变异与卵巢癌风险及分子基础研究
人多药耐药卵巢癌细胞株的建立及初步鉴定
